GlassScriptPhysician profile
Anna M Voltura
NPI 1285784140
$3,726.81
in general payments reported to CMS, 2019-2025
33 companies · $851 in 2025
The $851 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $73.98 · 2021: $259 · 2022: $12.63 · 2023: $674 · 2024: $1,664 · 2025: $851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,189.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sirius Medical Systems | $850.31 | 2023-2024 | Pintuition |
| Abbvie INC. | $757.67 | 2023-2025 | Natrelle Saline-Filled Breast Implants |
| Allergan, INC. | $278.43 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $222.79 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Merit Medical Systems INC | $206.39 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $203.05 | 2024-2025 | Enhertu, Tagrisso, Imfinzi |
| Novartis Pharmaceuticals Corporation | $202.00 | 2024-2025 | |
| Janssen Biotech, INC. | $108.78 | 2019-2024 | Balversa, Akeega, Erleada |
| Vertex Pharmaceuticals Incorporated | $93.02 | 2025 | |
| Incyte Corporation | $84.41 | 2024 | Jakafi, Monjuvi, Pemazyre |
| Exelixis INC. | $61.13 | 2024 | Cabometyx |
| Genzyme Corporation | $58.53 | 2019-2024 | |
| Aveo Pharmaceuticals, INC. | $52.50 | 2024 | |
| Hologic Sales and Service, LLC | $48.77 | 2024 | Trunode |
| Exeltis, USA INC. | $47.60 | 2025 | Slynd |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $45.05 | 2024 | Epkinly, Tivdak |
| Eisai INC. | $44.65 | 2024 | |
| Pfizer INC. | $37.89 | 2024 | |
| Alexion Pharmaceuticals, INC. | $34.65 | 2024 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $31.50 | 2024 | Alunbrig, Hyqvia |
| Tersera Therapeutics LLC | $27.85 | 2024 | Zoladex |
| Bayer Healthcare Pharmaceuticals INC. | $22.78 | 2024 | |
| Genentech USA, INC. | $22.67 | 2024 | Lunsumio, Polivy, Rozlytrek |
| Astellas Pharma US INC | $22.26 | 2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $21.75 | 2024 | Opdualag |
| Tempus Ai, INC | $20.63 | 2024 | |
| Springworks Therapeutics, INC. | $20.34 | 2024 | Ogsiveo |
| Celltrion USA INC. | $19.38 | 2024 | Vegzelma |
| Tactile Systems Technology INC | $19.00 | 2025 | Flexitouch Plus, Nimbl |
| Medtronic, INC. | $16.96 | 2025 | Inceptiv |
| Stryker Corporation | $15.24 | 2025 | Spy-Phi System |
| Ipsen Biopharmaceuticals, INC | $15.10 | 2024 | Onivyde |
| Karyopharm Therapeutics INC. | $13.73 | 2024 | Xpovio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Voltura listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.